T he arginine 132 (R132) mutation of isocitrate dehydrogenase -1 (IDH1 R132
) results in production of 2-hydroxyglutarate (2-H G) and is associated with a better prognosis compared with wild-type (WT ) in glioma patients. T he majority of lower-grade gliomas express IDH 1
R132
, whereas this mutation is rare in grade IV gliomas. T he aim of this study was to noninvasively investigate metabolic and physiologic changes associated with the IDH1 mutation in a mouse glioma model. Using a 7T magnet, we compared M RI and proton magnetic resonance spectroscopy (M RS) in U87 glioma cells overexpressing either the mutated IDH1 R132 or IDH1 wild-type (IDH1 WT ) gene in a mouse flank xenograft model. Flank tumors overexpressing IDH 1 R132 showed a resonance at 2.25 ppm corresponding to the 2-H G peak described for human IDH 1 R132 gliomas. WT tumors lacked this peak in all cases. IDH 1 mutant tumors demonstrated significantly reduced glutamate by in vivo M RS. T here were no significant differences in T 2 , apparent diffusion coefficient (ADC), or perfusion values between the mutant and IDH 1 WT tumors. T he IDH 1 R132 mutation results in 2-H G resonance at 2.25 ppm and a reduction of glutamate levels as deterKeywords: animal models, glioblastoma, glioma, isocitrate dehydrogenase 1 (IDH 1), M RI, M RS.
A comprehensive genomic analysis of human glioblastoma multiforme (GBM ) in 2008 revealed a mutation in the active site of isocitrate dehydrogenase -1 (I D H 1) (without loss of heterozygosity) in 12% of GBM patients. 1 O ver the past 3 years, additional studies have reported the presence of the I D H 1 mutation in acute myeloid leukemia, 2 -4 acute lymphoblastic leukemia, 5 prostate cancer, 5 colorectal cancer, 6 and melanoma.
7 Subsequent investigation confirmed the presence of a point mutation affecting arginine at residue 132 (R132) of the IDH 1 protein (IDH 1
) in . 70% of lower-grade gliomas. 8 The R132 residue is conserved among species, likely representing the substrate binding site. 9 I D H 1 R132 appears to be an early event in gliomagenesis before the emergence of the p53 mutation, 10 leading to the speculation that it contributes to malignant transformation. M edian overall survival among patients with anaplastic astrocytoma harboring mutations in either the I D H 1 or I D H 2 gene is significantly longer than that among patients without these 8 after oxidation to a -ketoglutarate. Reduced levels of a -ketoglutarate were reported as a consequence of I D H 1 R132 , 12 suggesting that this mutation may also influence metabolism. Whether oncogenic potential can derive from 2-H G, as previously speculated, 11, 13, 14 or from metabolic changes related to I D H 1 R132 is still under investigation.
Based on these data, 2-H G has been proposed as a potential biomarker for patients with glioma. Investigating this possibility, multiple researchers, 15 -17 including our own group, 18 have used proton magnetic resonance spectroscopy (M RS) to noninvasively measure 2-H G levels in human glioma patients. H owever, gliomas are heterogeneous tumors both genetically and metabolically, 19 so it is difficult to control for tumor differences not related to the IDH 1 mutation in human patients (eg, tumor grade or other oncogenic mutations). Conversely, the U87 mouse glioma model presents an opportunity to compare IDH 1 mutant and WT tumors in a controlled environment.
Thus, in this study, we used human U87 glioma cells transfected with I D H 1 R132 in order to study the consequences of IDH 1 R132 overexpression on tumor imaging features, physiology, and metabolism. This is the first step in establishing a well-characterized experimental model system in order to test the ability of noninvasive 2-H G measures to act as a biomarker of glioma growth and treatment response.
M ethods
Cell L ines and the Generation of Constructs All cells were cultured at 378C and 5% CO 2 in a 90% humidified tissue incubator. Culture medium was composed of Dulbecco's modified Eagle's medium/F12 medium supplemented with 10% fetal bovine serum (FBS), 2 mM glutamine, and 100 units/mL of penicillin/streptomycin. H uman WT I D H 1 coding sequences were amplified from U87 malignant glioma (M G) cells. The cDN A was fused in-frame with a FLAG tag at the C-terminus by the adapter primers (forward primer with the XhoI site underlined: 5 ′ -TAC TCG AG ATG TCCAAAAAAATCAG TG G -3 ′ , reverse primer with the EcoRI site underlined and the FLAG tag italicized: 5
′ -ACGAATTCTTACTTGTCAT CGTCATCCTTGTAATCCATAAGTTTGGCCTG-3 ′ ) and inserted into a XhoI-and EcoRI-linearized pLPCX vector. The I D H 1 R132H alteration was generated in 0.7 mg/mL puromycin. Protein expression was confirmed by immunoblot and immunofluorescence (data not shown).
Animal M odel
All animal experiments were approved by the University of California at Los Angeles Institutional Animal Care and Use Committee. M ale N O D-scid mice (6 -8 weeks old) were used for all experiments except 2-H G injection, where a phosphatase and tensin homolog (PTEN )/K-Ras knockout mouse was used (see below). Three groups of N O D-scid mice were injected with 10 6 glioma cells into the right flank as follows:
M agnetic Resonance I maging and 1
H M agnetic Resonance Spectroscopy
M RI and M RS were performed on a 7T Bruker system with a custom-built 2.2-cm radiofrequency birdcage coil. M ice were imaged at 14 and 21 days following glioma cell injections. Before imaging, we anesthetized the animals with isoflurane (4% induction, maintenance with 1.5% ). During imaging, respiration was monitored and isoflurane levels were adjusted if breathing was , 20 or . 60 breaths per minute. M ice were kept warm with water heated to 378C circulated using a TP500 water pump (Gaymar Solid State). To quantify T 2 2 mm 2 resolution; 1-mm slice thickness; N EX ¼ 2) was used to measure ADC. N onlinear least-squares regression was used to estimate ADC from multiple b-value DWIs and T 2 from M SM E data on a voxel-wise basis. Dynamic susceptibility contrast (DSC) perfusion M RI was collected using an EPI readout with 500 ms temporal resolution (2 slices; TR/ TE ¼ 500/7.18 ms; flip-angle ¼ 45 degrees; 312 2 mm 2 in-plane resolution; 0.5-mm slice thickness; N EX ¼ 1; 360 repetitions) following tail-vein injection of 0.05 mL of 0.5 mol/L gadolinium-based contrast agent steady-state magnetization, calculating the pre-bolus signal intensity on a voxel-wise basis, converting the truncated DSC-M RI time series to a concentration-time curve based on the T 2 * relaxivity of the contrast agent, and estimating relative tumor blood flow (rTBF) on a voxel-wise basis by using the first moment of the delta R2 (R2 ¼ 1/T2) curves to calculate mean transit time and with leakage correction to calculate tumor blood volume as described in a previous publication. 20 M RS was performed using a point-resolved spectroscopic sequence (TR/TE ¼ 4000/6.9 ms; N EX ¼ 512; 3-mL voxel volume within the tumor) and a variable pulse power and optimized relaxation delay water suppression scheme. 21 M RS data were quantified using the LCM odel, 22 and 2-H G was modeled based on J-coupling. 23 To optimize detection of 2-H G, M RS was performed on a 2-H G phantom (1-M concentration) using multiple TE times (6.9 -30 ms, with 5-ms increments). We found the strongest signal-to-noise ratio for the 2-H G peak in the spectra with the shortest TE (6.9 ms). Importantly, glutamate resonance (at 2.31 -2.35 ppm) was distinct from 2-H G resonance (at 2.24 -2.26 ppm). M etabolites with standard deviation (Cramer -Rao lower bounds) less than 20% of the estimated metabolite concentration were considered. Relative metabolite concentrations were expressed with respect to choline, since creatine levels were very low. This choice was justified by the lack of significant difference in the absolute choline concentration observed among the flank tumors.
Validation of 2-H G Chemical Shift on M RSin a PTEN / K-Ras Knockout M ouse
Validation of the precise 2-H G chemical shift on the M RS spectrum was determined by injecting exogenous 2-H G (Santa Cruz Biotechnology) into a PTEN /K-Ras knockout mouse 24 with a 3-mm optic glioma. This model was chosen to ensure maximum delivery of 2-H G to the tumor, since flank tumors have relatively poor perfusion and areas with limited contrast-agent uptake. Phosphate buffered saline (PBS) was used to prepare 1 M 2-H G solution, and pH was adjusted to 7.4. Serum concentration following a 0.1-mL injection of 1 M 2-H G for a 15-g mouse was 10 mM . M RS was performed before and 30 min after 2-H G injection with a similar protocol as previously described, with the exception of N EX ¼ 256 and a 2.5-mL voxel volume, which covered the tumor. from ≥ 2 adjacent sections by 2 experienced neuropathologists (W.Y. and L.M .). The percent of necrosis was calculated as necrotic area within the tumor v the whole area of the tumor and expressed as a fraction of 100 to the nearest decile. In addition, adjacent slices were processed with mouse anti-human antibody specific for IDH 1 R132H mutation 25 (Dianova) for immunohistochemistry. Sections were processed using the Dako EnVision + system (peroxidase) with blocking steps and secondary antibody dilutions per the manufacturer's instructions (DakoCytomation). N ovaRED (Vector Laboratories) was used as a chromogen. M ayer's hematoxylin was used as a counterstain.
Statistical Analysis

M RS metabolites, T 2 , and ADC values within different tumor volumes were analyzed using an analysis of variance (AN O VA) across groups (U87-IDH 1
R132
, U87-IDH 1 WT , U87-vector). The H olm -Sidak test for multiple pairwise comparisons was used for post hoc comparisons. Sigma Stat 11.0 (Systat Software) was used for AN O VA analysis. P , .05 was considered statistically significant. Data are given as means + standard deviation (SD) unless stated otherwise.
Results
Validation of 2-H G Chemical Shift Assignment in M RS Spectra
Validation of the chemical shift assigned to 2-H G on the 1 H -M R spectrum was performed using 0.1 mL of 1 M 2-H G solution injected into a PTEN /K-Ras mouse with an optic glioma. After 30 min following 2-H G injection, a distinct peak appeared at 2.25 ppm, the expected location based on J-coupling simulations using the LCM odel (Fig. 1B) . This chemical shift corresponded to the strongest peak of 2-H G (hydrogen attached to C-4 of 2-H G), similar to previously published results for 2-H G using J-coupling modeling and M RS. 23 
M easurement of 2-H G in Tumors O verexpressing I D H 1 R132
Q uantitative M RS using the LCM odel algorithm with J-coupling modeling for 2-H G confirmed the presence of a 2-H G peak in all U87 flank tumors overexpressing (Fig. 2D ). Fig. 3D ). Additionally, to decreased cell density and increased extracellular space, as expected for necrotic areas.
Q uantification of T 2 and AD C
M R Perfusion
Independent of IDH 1 R132 or IDH 1 WT expression, all flank tumors had a similar pattern of contrast enhancement, with an enhancing periphery and non-enhancing T 1 hypointense central region (Fig. 5A -C) . The slowestgrowing WT tumors had a slightly larger area of contrast enhancement compared with IDH 1 R132 and U87-vector tumors. Central regions exhibiting M R signal intensity consistent with necrosis exhibited very low perfusion, whereas regions with contrast enhancement on postcontrast T 1 -weighted images appeared to have elevated perfusion (Fig. 5D -F) . Relative TBF was not significantly different among flank tumors of IDH 1
R132
(mean + SEM ¼ 25.01 + 10.328 mL/100 mg tissue/ min), IDH 1 WT (22.29 + 7.748 mL/100 mg tissue/min), for IDH 1
, there were occasional cells that did not stain (Fig. 6D ). Whether these represented tumor cells that had lost I D H 1 R132 or connective cells from the vasculature or other sources is not clear (Fig. 6D) . H & E histology confirmed a necrotic area of 40% -50% (Fig. 6H ) in flank tumors overexpressing IDH 1 R132 compared with a region of necrosis of 10% -20% observed in IDH 1
WT and vector-control tumors ( Fig. 6E-H ).
Discussion
The current study is the first controlled experiment validating the link between noninvasive 2-H G detection using M RS and the I D H 1 R132 mutation in glioma cells. IDH 1 R132 overexpression in U87 cells led to in vivo detectable levels of 2-H G using M RS, providing further evidence of a causal relationship between the the glutamate and glutamine peaks. As expected, cells overexpressing IDH 1 WT lacked this metabolic peak. For our experiments, 2-H G levels were estimated to be between 10 mM and 20 mM in IDH 1 R132 flank tumors, somewhat higher than the 2 -9 mM range reported for humans. 16 The glutamate resonance (at 2.31 -2.35 ppm) was sufficiently distinct from the 2-H G resonance to prevent contamination of the 2-H G peak, which has been a limitation of 2-H G quantification in tumors with M RS performed on clinical (1.5T and 3T) scanners. Given the similarity of the IDH 1 mutant spectra in the current study with those previously published from in vivo human data, this use of IDH 1 R132 mutant overexpressing cell lines has provided further evidence that the IDH 1 R132 mutation is responsible for the 2-H G peak and that this resonance is not related to tumor grade or other confounding factors.
Reduced glutamate levels have previously been re- It is conceivable that this may be due to slight size differences in the mutant tumors within the context of the current experiment, as more rapid tumor growth could occur quicker than the angiogenesis necessary to maintain a normoxic environment. 18, 30, 31 Alternatively, elevated levels of 2-H G could potentially be toxic to the tumor cells, leading to more extensive necrotic area. In humans, 2-H G toxicity is suggested by the observation that inborn errors of metabolism resulting in elevated 2-H G levels result in encephalopathy.
32,33 Direct toxicity of 2-H G to rat cerebral cortical slices has been demonstrated (at 5-mM concentration), in similar concentrations to those of 2-H G reported for gliomas, 11, 14, 31 and within the range of 2-H G levels calculated for the xenografts used in our study. 11, 14, 34 O ne caveat to this assumption, however, is that IDH 1 mutant glioblastomas seem to have less necrosis than their WT counterparts, at least as detected by M RI. 35 In summary, we have demonstrated that overexpression of the IDH 1 mutation leads to detectable levels of 2-H G in a mouse glioma model that can be measured in vivo and noninvasively by M RS. This model system is of potential utility in establishing the relationships among 2-H G levels and treatment effect, outcomes, and other variables necessary to validate 2-H G as a clinically important biomarker for glioma.
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